Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy

BACKGROUND: Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Vivian W., Prosser, Connie, Kroeker, Karen I., Wang, Haili, Shalapay, Carol, Dhami, Neil, Fedorak, Darryl K., Halloran, Brendan, Dieleman, Levinus A., Goodman, Karen J., Fedorak, Richard N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450916/
https://www.ncbi.nlm.nih.gov/pubmed/25989340
http://dx.doi.org/10.1097/MIB.0000000000000376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450916/
https://www.ncbi.nlm.nih.gov/pubmed/25989340
http://dx.doi.org/10.1097/MIB.0000000000000376

Ejemplares similares